A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Prior treatment

• Concomitant disease, condition or treatment which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study.
• Use of any GD-related chaperone therapy within 4 weeks prior to Screening or expected need to initiate chaperone therapy during at least the first 18 months of the study.
• Any type of prior gene or cell therapy.
• Use of systemic immunosuppressant or steroid therapy other than protocol-specified immunosuppression.
• Participation in another therapeutic investigational drug or device study within 3 months or 5 half-lives of the study agent, whichever is longer.

Other illness

• Active and progressive bone disease expected to require surgical treatment in the next 6 months.
• History of total splenectomy or planned total splenectomy during the first 18 months of the study. (Partial splenectomy not exclusionary).
• Evidence of clinically significant liver disease, fragile liver, or history of exposure to hepatotoxins.
• Current diagnosis of unstable or clinically significant cardiovascular conditions based on Investigator assessment.
• History of certain cancers within 5 years of Screening.
• Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic)implants/cardiac pacemaker.

Lab values

• Thrombocytopenia with platelet count \< 40 × 10\^3 per μL.
• Severe hyperlipidemia (triglycerides \> 1,000 mg/dL).
• Women of childbearing potential, pregnant (i.e., positive serum pregnancy result at Screening and/or Check-in) or breastfeeding or intending to become pregnant during the course of the trial.
• Have an anti-AAV9 antibody titer of \>1:40 as determined by central laboratory.
• Clinically significant abnormalities in laboratory test results at Screening.

Other

• Clinically significant neurological signs and symptoms and/or behavioral disturbances.
• Splenomegaly \> 10 MN as evaluated by centrally read abdominal magnetic resonance imaging (MRI)

• Age greater or equal to 18 years at the time of informed consent.
• Bi-allelic pathogenic GBA1 variants must be centrally confirmed.
• On ERT or SRT for at least 2 years and on a stable, maximum tolerated dose, for at least 3 months prior to screening.
• Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Females and males will be eligible for this study. Men and women of childbearing potential must use a highly effective method of contraception consistently and correctly for the duration of the study, including the long-term follow-up.
• Patients must agree to abstain from blood, tissue and organ donation; and must agree to abstain from tissue and organ donation for the duration of the study, including long-term follow-up.